The termination of chemical neurotransmission in the central nervous system
(CNS) involves the rapid removal of neurotransmitter from synapses. This i
s fulfilled by specific transport systems in neurons and glia, including th
ose for gamma -aminobutyric acid (GABA), the main inhibitory neurotransmitt
er in the brain. Glial cells express the cloned Na+/Cl--dependent, high-aff
inity GABA transporters (GATs) GAT1, GAT2, and GAT3, as well as the low-aff
inity transporter BGT1. in situ hybridization and immunocytochemistry have
revealed that each transporter shows distinct regional distribution in the
brain and the retina. The neuronal vs. glial localization of the different
transporters is not clear-cut, and variations according to species, neighbo
ring excitatory synapses, and developmental stage have been reported. The l
ocalization, stoichiometry, and regulation of glial GATs are outlined, and
the participation of these structures in development, osmoregulation, and n
europrotection are discussed. A decrease in GABAergic neurotransmission has
been implicated in the pathophysiology of several CNS disorders, particula
rly in epilepsy. Since drugs which selectively inhibit glial but not neuron
al GABA uptake exert anticonvulsant activity, clearly the establishment of
the molecular mechanisms controlling GATs in glial cells will be an aid in
the chemical treatment of several CNS-related diseases. J. Neurosci. Res. 6
3: 461-468, 2001, (C) 2001 Wiley-Liss, Inc.